RecruitMe Clinical Trial

A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Nave Elderly Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
A study for patients with acute myeloid leukemia using study drug Venetoclax in combination with Azacitidine
Sponsor:AbbVie, Inc. Entire
Enrolling:Male and Female Patients
IRB Number:AAAR1251
Contact: Mark Frattini: 212-851-4872 / mgf2122@columbia.edu
Additional Study Information:

The purpose of this study is to evaluate the efficacy (how well the study drug works) and safety of venetoclax in combination with azacitidine in subjects who have not been treated for their acute myeloid leukemia (AML). The tolerability (the degree to which evident adverse effects can be tolerated by the patient) of venetoclax will also be evaluated.

Do You Qualify?
Do you have confirmed diagnosis of acute myeloid leukemia (AML)?YesNo
Are you older than 18 years of age?YesNo
Have you received experimental therapies for acute myeloid leukemia (AML)?YesNo
Investigator
Mark Frattini, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:

Mark Frattini

mgf2122@columbia.edu

212-851-4872

YesYesNo3